<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20936" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Eisenmenger Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Basit</surname>
            <given-names>Hajira</given-names>
          </name>
          <aff>Brookdale University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wallen</surname>
            <given-names>Tanner J.</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sergent</surname>
            <given-names>Bernie N.</given-names>
          </name>
          <aff>Appalachian Regional Healthcare</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hajira Basit declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tanner Wallen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bernie Sergent declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>13</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20936.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Eisenmenger syndrome (ES) is a constellation of symptoms that arise from a congenital heart defect and result in large anatomic shunts. Due to anatomic variations present at birth, hemodynamic forces initially result in a left-right shunt, which develops into severe pulmonary arterial hypertension (PAH) and elevated vascular resistance. Ultimately, due to increased pulmonary vascular resistance, the left-to-right shunt will become a right-to-left shunt, resulting in significant hypoxemia and cyanosis. This activity discusses the evaluation and treatment of Eisenmenger syndrome and further defines the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the pathophysiology of Eisenmenger syndrome.</p></list-item><list-item><p>Identify patients considered high risk for Eisenmenger syndrome</p></list-item><list-item><p>Evaluate&#x000a0;the physical exam findings associated with Eisenmenger syndrome.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst the interprofessional team to enhance care delivery for patients with Eisenmenger syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20936&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20936">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20936.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Eisenmenger syndrome is a&#x000a0;constellation of symptoms that&#x000a0;arise&#x000a0;from a&#x000a0;congenital heart defect&#x000a0;and result in large anatomic shunts. Due to anatomic variations&#x000a0;present at birth, hemodynamic&#x000a0;forces&#x000a0;initially result in&#x000a0;a left-right shunt,&#x000a0;which develops into&#x000a0;severe pulmonary arterial hypertension&#x000a0;(PAH)&#x000a0;and elevated vascular&#x000a0;resistance. Ultimately,&#x000a0;due to increased pulmonary vascular resistance,&#x000a0;the left-to-right shunt becomes a right-to-left shunt, resulting in significant hypoxemia and cyanosis. PAH is a mean pulmonary arterial pressure greater than 25 mmHg while resting or 30 mmHg when exercising. This may occur in large shunts or complex, unrepaired congenital heart disease as early as the first decade of life.&#x000a0;</p>
      </sec>
      <sec id="article-20936.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Any heart defect that leads to the development of PAH can cause Eisenmenger syndrome. This is commonly seen in atrial septal defects (ASD), ventricular septal defects (VSD), atrioventricular septal defects, and patent ductus arteriosus (PDA), but it can occur in more complex lesions as well. Unrepaired Tetralogy of Fallot may also result in Eisenmenger syndrome.&#x000a0;Without early repair, reversal of a left-to-right shunt may result in a bidirectional or right-to-left shunt. The subsequent hypoxemia due to this shunt may not be responsive to oxygen.</p>
      </sec>
      <sec id="article-20936.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Eisenmenger syndrome is a relatively rare disorder that is usually seen in persons with poor healthcare access (ie, rural/underserved areas), in whom large anatomical defects may go undetected for many years.</p>
      </sec>
      <sec id="article-20936.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The most common defects leading to&#x000a0;Eisenmenger syndrome are ASD, VSD, and PDA defects. The following&#x000a0;3 main processes result in the ultimate reversal of a left-to-right into a right-to-left shunt:&#x000a0;</p>
        <list list-type="order">
          <list-item>
            <p>Vasoconstriction, which is&#x000a0;due to imbalances&#x000a0;in pulmonary&#x000a0;vascular tone,&#x000a0;followed by</p>
          </list-item>
          <list-item>
            <p>Vascular&#x000a0;remodeling, which is&#x000a0;due&#x000a0;to the proliferation of pulmonary vascular smooth muscle,&#x000a0;and&#x000a0;finally</p>
          </list-item>
          <list-item>
            <p>Thrombosis, which is caused by the increased resistance of blood flow.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20936.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histological examination of the vasculature in Eisenmenger syndrome would resemble other forms of pulmonary hypertension. Increased proliferation of vascular smooth muscle, evidence of lung parenchymal scarring (pulmonary fibrosis), and decreased luminal&#x000a0;caliber due to cellular proliferation&#x000a0;in the vascular walls all&#x000a0;are indicative of a PAH process.&#x000a0;</p>
      </sec>
      <sec id="article-20936.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common presentation in Eisenmenger syndrome is a patient with known congenital heart disease (CHD) presenting with worsening exertional dyspnea. Other common complaints may include swelling, volume retention, syncope, worsening cyanosis, palpitations, or hemoptysis.&#x000a0;Due to the increase in red blood cell volume from chronic hypoxemia, patients&#x000a0;also&#x000a0;may present with polycythemia/viscosity-type symptoms such as dizziness, headaches, vision changes, end-organ damage, stroke. Digital clubbing is often seen in these patients. Digital clubbing that is more pronounced in the lower extremities&#x000a0;can occur in the setting of shunt physiology associated with patent&#x000a0;ductus arteriosus and the delivery of unoxygenated&#x000a0;blood distal to the origin of the left subclavian artery. Dermatologic&#x000a0;manifestations associated with Eisenmenger's syndrome may include plethora, livedo reticularis, profound acrocyanosis, urate depositions, ecchymosis, and ischemic skin ulcerations. Ascites and right upper quadrant tenderness, as a result of hepatic congestion and gallbladder pathology, may be present on abdominal exam.</p>
      </sec>
      <sec id="article-20936.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>All patients with suspicion for Eisenmenger syndrome should undergo a detailed history and physical, with&#x000a0;particular attention&#x000a0;on determining triggers for PAH. Patients should also undergo an evaluation to determine the degree of PAH as well as ventricular function.&#x000a0;As there is evidence supporting symptomatic improvement with vasodilator therapy as in PAH, patients should also undergo vasoreactivity testing.&#x000a0;Workup should include pulse oximetry, chest radiograph, EKG, pulmonary function tests, complete blood count, iron studies, and cytidine monophosphate testing. Complete cardiac catheterization should occur at centers that specialize in the management of adult congenital heart disease and PAH.&#x000a0;Loud murmurs may not be present in Eisenmenger syndrome. In such cases, left ventricle pressure may be&#x000a0;similar to&#x000a0;right ventricle pressure, creating a very small gradient. Without turbulence, there is no readily appreciable murmur on auscultation.&#x000a0;</p>
      </sec>
      <sec id="article-20936.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Cardiopulmonary transplantation is curative for Eisenmenger syndrome. However, this is impractical in most&#x000a0;settings. Pharmacology has improved symptoms but not mortality. Potential pharmaceuticals for the treatment of Eisenmenger syndrome include diuretics, antiarrhythmics, and anticoagulation in some patients.&#x000a0;Supplemental oxygen has not definitively shown to have a mortality benefit.&#x000a0;Vasodilator&#x000a0;therapies may provide an opportunity for clinical research, and&#x000a0;studies have shown&#x000a0;some symptomatic improvement.&#x000a0;The&#x000a0;Bosentan&#x000a0;Randomized Trial of Endothelin Antagonist Therapy-5 trial showed improved exercise capacity and symptomatic improvement&#x000a0;with endothelin antagonists&#x000a0;in&#x000a0;patients with ASD, VSD, and PDA with&#x000a0;Eisenmenger syndrome <xref ref-type="bibr" rid="article-20936.r1">[1]</xref>. Subsequent studies show mortality benefits with sildenafil as well.&#x000a0;Warfarin has been classically used for anticoagulation in&#x000a0;Eisenmenger syndrome. In theory, anticoagulation may&#x000a0;dispel some of the pathology related to in situ thrombosis inherent with the disease.&#x000a0;However, the evidence for this&#x000a0;practice is based on mostly observational studies.&#x000a0;</p>
        <p>Clinical follow-up should&#x000a0;focus on checking annual CBC, iron studies, kidney function, and uric acid, with a focus on correcting any abnormalities. Patients&#x000a0;also&#x000a0;should be assessed with pulse&#x000a0;oximetry, both with and without supplemental O2. Any abnormalities&#x000a0;suggesting hypoxemia warrant further evaluation.&#x000a0;Surgical correction of the&#x000a0;causative&#x000a0;heart defect in adult patients is generally contraindicated <xref ref-type="bibr" rid="article-20936.r2">[2]</xref>. In patients who have developed PAH as a consequence of unrepaired CHD, the defect itself may be acting as a protective measure, preventing worsening of the&#x000a0;pulmonary&#x000a0;vascular resistance in the face of increasing right ventricular pressure<xref ref-type="bibr" rid="article-20936.r3">[3]</xref>. In children, the development of pulmonary vascular disease (greater than 6 Woods units/m2) with poor vasodilator response is likely to face post-surgical complications, including right heart failure, increased pulmonary hypertension, and hypertensive crises.&#x000a0;Classically, it is thought to be of little benefit to undergo such risky procedures with&#x000a0;a plethora of&#x000a0;potential consequences. Additionally, even with clinical response to vasodilator therapies for the pulmonary arterial hypertension component, there are only a select few case reports that show benefit for the closure of the anatomical defect. However, there is promising evidence that cardiac surgery and close peri- and post-operational management of pulmonary vascular resistance with advanced PAH therapies may improve safety and mitigate downstream problems.<xref ref-type="bibr" rid="article-20936.r4">[4]</xref><xref ref-type="bibr" rid="article-20936.r5">[5]</xref><xref ref-type="bibr" rid="article-20936.r6">[6]</xref><xref ref-type="bibr" rid="article-20936.r7">[7]</xref><xref ref-type="bibr" rid="article-20936.r8">[8]</xref></p>
      </sec>
      <sec id="article-20936.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Due to similar presentation and resemblances of the underlying pathophysiology, other causes of pulmonary hypertension should be ruled out.&#x000a0;Certain rheumatological and autoimmune diseases, such as mixed connective tissue disorder, scleroderma, and systemic lupus&#x000a0;erythematosus, may have similar presentations. Hepatitis B, C, and HIV serologies&#x000a0;also&#x000a0;must be considered, as these may have systemic vascular presentations.&#x000a0;</p>
      </sec>
      <sec id="article-20936.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with Eisenmenger syndrome have reduced life expectancies, with high mortality in the third&#x000a0;and fourth&#x000a0;decades.&#x000a0;Ventricular failure, hemoptysis, pregnancy complications, and strokes are common causes of death.&#x000a0;</p>
      </sec>
      <sec id="article-20936.s12" sec-type="Complications">
        <title>Complications</title>
        <p>In patients with Eisenmenger syndrome,&#x000a0;certain&#x000a0;conditions should be avoided such as pregnancy,&#x000a0;dehydration, isometric exercise, iron deficiency anemia, and significant time spent at high altitudes. When prescribing&#x000a0;antihypertensives, caution should be exercised when using peripheral vasodilating agents, which may cause worsening of the right-left shunt.&#x000a0;Due to in-situ thrombosis and reactive erythrocytosis, patients with Eisenmenger syndrome are likely to exhibit evidence of both a bleeding diathesis and a hypercoagulable&#x000a0;state. Patients are at higher risks for paradoxical emboli, in which a clot may theoretically pass through a septal defect from the right heart, bypass the lungs, and instead enter the systemic or cerebrovascular&#x000a0;circulation. This may result in&#x000a0;devastating&#x000a0;cerebrovascular accidents.&#x000a0;</p>
      </sec>
      <sec id="article-20936.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about&#x000a0;Eisenmenger syndrome include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Loud murmurs may not be present in severe Eisenmenger syndrome due to the lack of a pressure gradient between ventricles and, therefore, low turbulence that would otherwise produce them.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Hypoxemia that is responsive to oxygen therapy should be treated.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>In women who develop PAH with CHD, pregnancy is contraindicated.&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20936.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Eisenmenger syndrome is best managed by an interprofessional team that includes a cardiologist, pulmonologist, cardiac surgeon, internist, thoracic surgeon, and intensivist. The disorder has many causes, and the key is to treat the primary disorder. Once Eisenmenger syndrome develops, the prognosis is poor. Heart and lung transplants are an option, but the lack of donors is a problem. Medications to dilate the pulmonary vasculature are unreliable or consistent in efficacy. Most patients are dead within 12 to 24 months after the diagnosis is made.<xref ref-type="bibr" rid="article-20936.r9">[9]</xref><xref ref-type="bibr" rid="article-20936.r10">[10]</xref><xref ref-type="bibr" rid="article-20936.r11">[11]</xref></p>
      </sec>
      <sec id="article-20936.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20936&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20936">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/heart-health/eisenmenger-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20936">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20936/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20936">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20936.s16">
        <title>References</title>
        <ref id="article-20936.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gali&#x000e8;</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Beghetti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gatzoulis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Granton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chiossi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Landzberg</surname>
                <given-names>M</given-names>
              </name>
              <collab>Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators</collab>
            </person-group>
            <article-title>Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Jul</month>
            <day>04</day>
            <volume>114</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-54</page-range>
            <pub-id pub-id-type="pmid">16801459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>LY</given-names>
              </name>
            </person-group>
            <article-title>Eisenmenger syndrome: not always inoperable.</article-title>
            <source>Respir Care</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>57</volume>
            <issue>9</issue>
            <fpage>1488</fpage>
            <page-range>1488-95</page-range>
            <pub-id pub-id-type="pmid">22348268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warnes</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Bashore</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Child</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Dearani</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Del Nido</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fasules</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Hijazi</surname>
                <given-names>ZM</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Landzberg</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Miner</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2008</year>
            <month>Dec</month>
            <day>02</day>
            <volume>52</volume>
            <issue>23</issue>
            <fpage>e143</fpage>
            <page-range>e143-e263</page-range>
            <pub-id pub-id-type="pmid">19038677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhatt</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kuehl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alpert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brabeck</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Crumb</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davidson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Earing</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Ghoshhajra</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Karamlou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mital</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ting</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>ZH</given-names>
              </name>
              <collab>American Heart Association Council on Clinical Cardiology</collab>
            </person-group>
            <article-title>Congenital heart disease in the older adult: a scientific statement from the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>May</month>
            <day>26</day>
            <volume>131</volume>
            <issue>21</issue>
            <fpage>1884</fpage>
            <page-range>1884-931</page-range>
            <pub-id pub-id-type="pmid">25896865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hartwig</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Schultze</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Review of evidence for bosentan therapy for treatment of Eisenmenger syndrome.</article-title>
            <source>J Am Assoc Nurse Pract</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>72</fpage>
            <page-range>72-77</page-range>
            <pub-id pub-id-type="pmid">30475252</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nashat</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Montanaro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kempny</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wort</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gatzoulis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Babu-Narayan</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Atrial septal defects and pulmonary arterial hypertension.</article-title>
            <source>J Thorac Dis</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>10</volume>
            <issue>Suppl 24</issue>
            <fpage>S2953</fpage>
            <page-range>S2953-S2965</page-range>
            <pub-id pub-id-type="pmid">30305956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Condliffe</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Clift</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tulloh</surname>
                <given-names>RMR</given-names>
              </name>
            </person-group>
            <article-title>Management dilemmas in pulmonary arterial hypertension associated with congenital heart disease.</article-title>
            <source>Pulm Circ</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>2045894018792501</fpage>
            <pub-id pub-id-type="pmid">30033821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fathallah</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krasuski</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>A Multifaceted Approach to Pulmonary Hypertension in Adults With Congenital Heart Disease.</article-title>
            <source>Prog Cardiovasc Dis</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>61</volume>
            <issue>3-4</issue>
            <fpage>320</fpage>
            <page-range>320-327</page-range>
            <pub-id pub-id-type="pmid">30031003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katsurahgi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kamiya</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yamanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Neki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miyoshi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Iwanaga</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Horiuchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoshimatsu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Niwa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ogo</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Maternal and fetal outcomes in pregnancy complicated with Eisenmenger syndrome.</article-title>
            <source>Taiwan J Obstet Gynecol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>58</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-187</page-range>
            <pub-id pub-id-type="pmid">30910135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vijarnsorn</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Durongpisitkul</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chungsomprasong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bositthipichet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ketsara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Titaram</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chanthong</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kanjanauthai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soongswang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts.</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>e0195092</fpage>
            <pub-id pub-id-type="pmid">29664959</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20936.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clav&#x000e9;</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>CRP</given-names>
              </name>
              <name>
                <surname>Bydlowski</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Factors influencing outcomes in patients with Eisenmenger syndrome: a nine-year follow-up study.</article-title>
            <source>Pulm Circ</source>
            <year>2017</year>
            <season>Jul-Sep</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>635</fpage>
            <page-range>635-642</page-range>
            <pub-id pub-id-type="pmid">28704136</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
